[Correspondence] Carfilzomib for relapsed or refractory multiple myeloma – Authors' reply

In the randomised, phase 3 ENDEAVOR trial in patients with relapsed or refractory multiple myeloma, we showed that treatment with carfilzomib and dexamethasone compared with bortezomib and dexamethasone significantly improved progression-free survival (18·7 months with carfilzomib vs 9·4 months with bortezomib; hazard ratio [HR] 0·53 [95% CI 0·44–0·65]; p<0·0001) and overall survival (47·6 vs 40·0 months; HR 0·79 [0·65–0·96], p=0·010).1,2 ENDEAVOR was the first head-to-head study of two different proteasome inhibitors in relapsed or refractory multiple myeloma, and these results established the combination of carfilzomib administered at 56 mg/m2 twice weekly with dexamethasone as a new standard of care in this disease setting.

http://ift.tt/2C9wDXX